About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren's contracture and Peyronie's disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren's contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: BSTC
- CUSIP: 09093110
- Previous Close: $50.49
- 50 Day Moving Average: $52.29
- 200 Day Moving Average: $46.89
- 52-Week Range: $31.32 - $58.21
- Trailing P/E Ratio: 33.22
- Foreward P/E Ratio: 29.17
- P/E Growth: 1.48
- Market Cap: $360.85M
- Outstanding Shares: 7,147,000
- Beta: 1.31
- Net Margins: 43.13%
- Return on Equity: 22.74%
- Return on Assets: 19.88%
Companies Related to BioSpecifics Technologies Corp.:
- Current Ratio: 21.57%
- Quick Ratio: 21.57%
What is BioSpecifics Technologies Corp.'s stock symbol?
BioSpecifics Technologies Corp. trades on the NASDAQ under the ticker symbol "BSTC."
Where is BioSpecifics Technologies Corp.'s stock going? Where will BioSpecifics Technologies Corp.'s stock price be in 2017?
2 brokerages have issued 1 year price targets for BioSpecifics Technologies Corp.'s stock. Their predictions range from $60.00 to $60.00. On average, they expect BioSpecifics Technologies Corp.'s share price to reach $60.00 in the next year.
When will BioSpecifics Technologies Corp. announce their earnings?
BioSpecifics Technologies Corp. is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.
Who owns BioSpecifics Technologies Corp. stock?
BioSpecifics Technologies Corp.'s stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.66%), Dimensional Fund Advisors LP (3.21%), Numeric Investors LLC (2.16%), State Street Corp (1.15%), JW Asset Management LLC (1.03%) and RK Capital Management LLC (0.99%). Company insiders that own BioSpecifics Technologies Corp. stock include Paul Gitman, Thomas Wegman and Toby Wegman.
Who sold BioSpecifics Technologies Corp. stock? Who is selling BioSpecifics Technologies Corp. stock?
BioSpecifics Technologies Corp.'s stock was sold by a variety of institutional investors in the last quarter, including RK Capital Management LLC, Royce & Associates LP, Two Sigma Investments LP, Oxford Asset Management, Allianz Asset Management AG, GSA Capital Partners LLP, Hatteras Funds LP and Putnam Investments LLC. Company insiders that have sold BioSpecifics Technologies Corp. stock in the last year include Thomas Wegman and Toby Wegman.
Who bought BioSpecifics Technologies Corp. stock? Who is buying BioSpecifics Technologies Corp. stock?
BioSpecifics Technologies Corp.'s stock was bought by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Renaissance Technologies LLC, Russell Investments Group Ltd., Dimensional Fund Advisors LP, Cigna Investments Inc. New, AQR Capital Management LLC, State Street Corp and A.R.T. Advisors LLC.
How do I buy BioSpecifics Technologies Corp. stock?
Shares of BioSpecifics Technologies Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of BioSpecifics Technologies Corp. stock cost?
One share of BioSpecifics Technologies Corp. stock can currently be purchased for approximately $50.46.